SOLTI-2402 TOP-REAL

Patient-Centered Study of Trastuzumab Deruxtecan (T-DXd) in First-Line HER2-POsitive Metastatic Breast Cancer with Proactive Toxicity Management Reflecting Real-World Clinical Practice / TOP-REAL Trial

Methodology

Trial Organization & Centers

Sponsor
  • SOLTI
Collaborator(s)
  • UNICANCER West German Study Group AstraZeneca Daiichi Sankyo
Researchers

Cristina Saura, MD, PhD Vall d’Hebron University Hospital/Vall d’Hebron Institute of Oncology (VHIO)

Inês Vaz-Luis, MD, PhD Cancer Survivorship Group, PRISM, Gustave Roussy

Nadia Harbeck, MD, PhD Munich
LMU University Hospital

Santiago Escrivá de Romaní, MD, PhD Vall d’Hebron University Hospital/Vall d’Hebron Institute of Oncology (VHIO)

Methodology

Trial Design & Schema

Diseño del estudio